Aaron Levine, PhD, MPhil
Vice – Chair (June 2019-2020)
Georgia Tech
Atlanta, GA, United States

[1] Imbach KJ, Patel A, and Levine AD. Ethical considerations in the translation of CAR-T cell therapies. Cell & Gene Therapy Insights 2018;4 (4): 295-307. https://insights.bio/cell-and-gene-therapy-insights/journal/articles/ethical-considerations-in-the-translation-of-car-t-cell-therapies/

[2] Dodson BP and Levine AD. Challenges in the commercialization and translation of cell therapies. BMC Biotechnology 2015; 15:70. https://bmcbiotechnol.biomedcentral.com/articles/10.1186/s12896-015-0190-4

[3] Levine AD and Wolf LE. The roles and responsibilities of physicians in patients’ decisions about unproven stem cell therapies. Journal of Law, Medicine & Ethics 2012;40(1) 122-34. https://journals.sagepub.com/doi/10.1111/j.1748-720X.2012.00650.x

[4] Ryan KA, Sanders AN, Wang DD and Levine AD. Tracking the rise of stem cell tourism. Regenerative Medicine 2010;5(1): 27-33. https://www.futuremedicine.com/doi/abs/10.2217/rme.09.70